Mainly eliminated in unchanged form, in minor parts metabolised by CYP 2C9. One reference and clinical observations point to non- porphyrinogenicity.

(To be edited, initial data ST OCT 04) Angiotensin II receptor antagonist. Mainly eliminated in unchanged form, to a lesser extent metabolized in the liver by 2C9. Less potent inhibitor of CYP 2C9. Thunell, patient reports (n=5): tolerated. Andersson, patient report (n=1): tolerated. French list: authorized

Uneventful use reported in 44 patients with acute porphyria.